Ivelin Georgiev

November 6, 2023

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.

By Bill Snyder
The study team includes, from left, Maribeth Nicholson, MD, MPH, Ben Spiller, PhD, Buddy Creech, MD, MPH, Borden Lacy, PhD, Eric Skaar, PhD, MPH, Isaac Thomsen, MD, MSCI, Ivelin Georgiev, PhD, and Danyvid Olivares-Villagomez, PhD.
March 30, 2023

NIH grant launches C. diff vaccine research initiative

Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.

By Anthony Czelusniak
February 2, 2023

Discovery of “cross-reactive” antibodies could aid treatment of viral co-infections

By Bill Snyder
January 12, 2023

Antibody “fingerprinting” method potential advance to slow spread of dengue

Vanderbilt researchers have reported a major advance in understanding and potentially preventing dengue, a devastating, mosquito-borne tropical viral infection that is spreading across the globe.

By Bill Snyder
The study team included (front row, from left) Kelsey Voss, PhD, Rachel Bonami, PhD, Erin Wilfong, MD, PhD, (back row, from left) Jonathan Irish, PhD, Jeff Rathmell, PhD, and Ivelin Georgiev, PhD.
July 20, 2022

Vanderbilt team tracks cellular and antibody responses to COVID-19 vaccine

In a technical tour de force, a collaborative team of Vanderbilt researchers has characterized the antigen-specific immune response to the Pfizer SARS-CoV-2 RNA vaccine.

By Leigh MacMillan
March 24, 2022

Grant set to support Georgiev’s research to identify new antibodies

Vanderbilt’s Ivelin Georgiev, PhD, has received a three-year, $750,000 award from The G. Harold and Leila Y. Mathers Foundation of Rye Brook, New York, to support research aimed at rapidly identifying potent, disease-fighting antibodies.

By Bill Snyder
March 10, 2022

Technique hastens COVID-19 antibody discovery

Optimization of a technique developed at Vanderbilt University Medical Center enables rapid and efficient identification of neutralizing monoclonal antibodies against the virus that causes COVID-19.
By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.
By Bill Snyder
October 29, 2020

Grant helps expand VI4’s Artist-in-Residence program

An innovative Vanderbilt program that brings together scientists and artists with the shared goal of scientific communication is set to expand with support from a three-year grant from the Burroughs Wellcome Fund.
By Leigh MacMillan
June 23, 2020

Two VUMC researchers named 2020 Chancellor Faculty Fellows

Two Vanderbilt University Medical Center researchers -- Jennifer (Piper) Below, PhD, associate professor of Medicine, and Ivelin Georgiev, PhD, associate professor of Pathology, Microbiology and Immunology -- have been selected for the 2020 cohort of Chancellor Faculty Fellows at Vanderbilt University.
By Bill Snyder
December 12, 2019

New tool may speed antibody, vaccine research

By Allison Whitten
June 8, 2018

A “public” target for HIV

Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.
By Bill Snyder